JG
IRLA

Jefferies Group’s IRulya Therapeutics Inc. Common Stock IRLA Stock Holding History

Jefferies Group’s Portfolio IRLA Stock Details IRLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-101
Closed -$256K – 1879
2021
Q4 		$256K Buy
101
+32
+46% +$195K ﹤0.01% 1331
2021
Q3 		$1.26M Sell
69
-174
-72% -$2.77M 0.01% 909
2021
Q2 		$2.57M Buy
+243
New +$2.04M 0.02% 664

Other funds holding IRLA

ECG
EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Voloridge Investment Management
Voloridge Investment Management Jupiter, Florida $23.5B AUM 33.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Jefferies Group's IRLA Position: Q1 2022 in Review

Jefferies Group sold out of IRulya Therapeutics Inc. Common Stock (IRLA) in Q1 2022, closing a stake of 101 shares — an estimated $256K sold.

Jefferies Group first reported a position in IRLA in Q2 2021 and held it in 3 quarters. The position peaked at $2.57M in Q2 2021. 85 funds tracked by Wall St. Rank hold IRLA as of Q1 2022.

  • Jefferies Group reported no remaining IRulya Therapeutics Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Jefferies Group sold 101 IRulya Therapeutics Inc. Common Stock shares in Q1 2022, an estimated $256K.
  • Jefferies Group first reported a position in IRulya Therapeutics Inc. Common Stock in Q2 2021 and held it in 3 quarters.
  • Jefferies Group's IRulya Therapeutics Inc. Common Stock position peaked at $2.57M in Q2 2021.
  • 85 funds tracked by Wall St. Rank held IRulya Therapeutics Inc. Common Stock as of Q1 2022.

Based on Jefferies Group's 13F filing for Q1 2022, filed 16 May 2022.